Fig. 2
From: Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Kaplan–Meier curves of progression free survival of patients treated with platinum-based chemotherapy, according to the ALK fusion variants. a EML4 (N = 27) versus non-EML4 (N = 13). b Demonstration of progression free survival of each variant (v1, N = 17; v2, N = 1; v3a/b, N = 9; non-EML4, N = 13). Each symbol on the plot marks a censored patient. v1, EML4-ALK variant 1; v2, EML4-ALK variant 2; v3a/b, EML4-ALK variant 3a/b